期刊文献+

正常纯化尿路上皮细胞蛋白质表达谱鉴定

PROTEOMIC EXPRESSION PROFILE OF PURIFIED NORMAL UROTHELIUM
下载PDF
导出
摘要 目的研究正常尿路上皮细胞的蛋白质表达谱,为尿路上皮癌蛋白质芯片的研制奠定基础。方法采用激光捕获显微切割技术从正常膀胱黏膜获得纯化的尿路上皮细胞,二维液相色谱电喷雾串联质谱鉴定标本中的蛋白质表达。应用生物信息学软件以及基因本体论(GO)工具分析鉴定蛋白质。结果共鉴定218个蛋白质,其中19个为假定蛋白质,11个为疏水性蛋白质,40个蛋白质等电点(PI)>9,42个蛋白质相对分子质量<104或者>105,13个蛋白具有跨膜结构。按GO划分218个蛋白质中具有生物学途径、细胞成分、分子功能注解的蛋白质分别为155、148、173个,浓集与缺失表达的GO术语分别为34/15、24/7、26/14个。结论本研究为尿路上皮癌生物标记组研究提供了有效的候选蛋白。 Objective To study the proteomic expression profile of normal human urothelium so as to establish basis for constructing urothelium carcinoma protein chips. Methods Pure urothelium cells from normal bladder epithelium were harvested by laser capture microdissection(LCM),and the proteomic expression profile was identified by two-dimensional liquid chromatography tandem mass spectrometry(2D-LC-MS/MS).The identified proteins were analyzed by bioinformatic softwares and gene ontology(GO) tools. Results A total of 218 proteins were identified,of which,19 were hypothetic proteins and 11 were hydrophobic proteins.There were 40(18.3%) proteins with PI 9 and 42(19.3%) proteins with MW104 or MW105,13 proteins had transmembrane structure.According to GO category,of the 218 proteins,155(71.1%) had biological process annotation,148(67.9%) with cellular component annotation and 173(79.4%) with molecular function annotation.The category enrichment/depletion in three ontologies were 34/15,24/7 and 26/14,respectively. Conclusion The results of this study present candidate proteins for the research of biomarker of urothelial carcinoma.
出处 《青岛大学医学院学报》 CAS 2011年第2期156-157,160,共3页 Acta Academiae Medicinae Qingdao Universitatis
关键词 膀胱 上皮细胞 质谱分析法 urinary bladder epithelial cells mass spectrometry
  • 相关文献

参考文献7

  • 1NIU H T, ZHANG Y B, JIANG H P, et al. Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urothelium[J]. Urol Oncol, 2009,27(4):400-406.
  • 2OHLSSON G, MOREIRA J M, GROMOV P, et al. Loss of expression of the adipocyte type fatty acid binding protein (A- FABP) is associated with progression of human urmhelial car cinomas[J]. Mol Cell Proteomics, 2005,4 : 570-581.
  • 3SHENG K H, YAO Y C, CHUANG S S, et al. Search for the tumor related proteins of transition cell carcinoma in Tai wan by proteomic analysis[J]. Proteomics, 2006, 6: 1058- 1065.
  • 4MEMON A A, CHANG J W, OH B R, et al. Identification of differentially expressed proteins during human urinary bladder cancer progression[J]. Cancer Detect Prey, 2005, 29:249-255.
  • 5王延涛,沈方臻,侯继院.低剂量顺铂并IFN-α对小鼠移植性肝癌血管生成影响[J].青岛大学医学院学报,2008,44(1):37-40. 被引量:7
  • 6VALENTINO L, PIERRE J. JAK/STAT signal transduc tion: regulators and implication in hematological malignancies [J]. 2006,71:713-721.
  • 7GASTON K E, GROSSMAN H B Y. Proteomic assays for the detection of urothelial cancer[J]. Methods Mol Biol, 2010, 641:303-323.

二级参考文献11

  • 1谭光宏,魏于全,田聆,黄风迎.猪endoglin重组蛋白疫苗和低剂量顺铂联合治疗肿瘤研究[J].海南医学院学报,2006,12(1):13-19. 被引量:3
  • 2沈方臻,王秀美,陈滇宝.富勒醇对小鼠移植性肝癌抑瘤作用的初步研究[J].青岛大学医学院学报,2006,42(3):242-243. 被引量:5
  • 3MILLER K D, SWEENEY C J, SLEDGE G W J R. Redefi-ning the target: chemotherapeutics as antiangiogenics[J]. J Clin Oncol, 2001,19(4):1195-1206.
  • 4BELLO L, CARRABBA G, GIUSSANI C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo[J]. Cancer Res, 2001,61(20): 7501-7506.
  • 5TANAKA F, OYANAGI H, TAKENAKA K, et al. Glomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer[J]. Cancer Res, 2003,63(20):6791-6794.
  • 6FOLKMAN J. What is the evidence that tumors are angioge-nesis dependent[J]? J Natl Cancer Inst, 1990,82(1):4-6.
  • 7KERBEL R S. Tumor angiogenesis: past, present and the near future [J]. Carcinogenesis, 2000,21(3):505-515.
  • 8KLEMENT G, HUANG P, MAYER B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts [J]. Clin Cancer Res, 2002,8(1):221-232.
  • 9GATELY S, KERBEL R. Antiangiogenic scheduling of lower dose cancer chemotherapy[J]. Cancer J, 2001,7(5):427-436.
  • 10BROWDER T, BUTTERFIELD C E, KRA LING B M, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer [J]. Cancer Res, 2000,60(7):1878-1886.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部